About Delcath Systems, Inc.
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver.
2BB score and signals
Delcath Systems, Inc.’s current 2BB score is 39 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 29 | Low |
| Momentum | 23 | Weakening |
| Financial strength | 78 | Strong |
| Quality | 100 | Very Strong |
| Risk | 36 | Low |
Company facts
| CEO | Gerard Michel |
| Headquarters | Queensbury, New York, United States |
| Founded | 1988 |
| Employees | 156 |
| P/E ratio | 2,800.33 |
| 52-week range | $8.12 – $17.42 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-22 | — | -0.1244 | — | $26.88M |
| 2026-11-02 | — | -0.0796 | — | $26.55M |
| 2026-08-06 | — | -0.0918 | — | $26.78M |
| 2026-05-07 | -0.03 | -0.0884 | $24.99M | $23.85M |
Related companies
